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Abstract
Background: Ovarian germ cell tumours (OGCTs) typically arise in young females and their
pathogenesis remains poorly understood. We investigated the origin of malignant OGCTs and
underlying molecular events in the development of the various histological subtypes of this
neoplasia.
Results: We examined in situ expression of stem cell-related (NANOG, OCT-3/4, KIT, AP-2γ) and
germ cell-specific proteins (MAGE-A4, NY-ESO-1, TSPY) using a tissue microarray consisting of 60
OGCT tissue samples and eight ovarian small cell carcinoma samples. Developmental pattern of
expression of NANOG, TSPY, NY-ESO-1 and MAGE-A4 was determined in foetal ovaries
(gestational weeks 13–40). The molecular genetic part of our study included search for the
presence of Y-chromosome material by fluorescence in situ hybridisation (FISH), and mutational
analysis of the KIT oncogene (exon 17, codon 816), which is often mutated in testicular GCTs, in a
subset of tumour DNA samples. We detected a high expression of transcription factors related to
the embryonic stem cell-like pluripotency and undifferentiated state in OGCTs, but not in small cell
carcinomas, supporting the view that the latter do not arise from a germ cell progenitor. Bilateral
OGCTs expressed more stem cell markers than unilateral cases. However, KIT was mutated in 5/
13 unilateral dysgerminomas, whereas all bilateral dysgerminomas (n = 4) and all other histological
types (n = 22) showed a wild type sequence. Furthermore, tissue from five phenotypic female
patients harbouring combined dysgerminoma/gonadoblastoma expressed TSPY and contained Y-
chromosome material as confirmed by FISH.
Conclusion: This study provides new data supporting two distinct but overlapping pathways in
OGCT development; one involving spontaneous KIT mutation(s) leading to increased survival and
proliferation of undifferentiated oogonia, the other related to presence of Y chromosome material
and ensuing gonadal dysgenesis in phenotypic females.
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The three main categories of ovarian tumours are: surface
epithelium-stromal tumours, sex-cord tumours and germ
cell tumours (GCTs; benign and malignant). Malignant
ovarian (OGCTs) have a median age at onset of 18 years
and represent approximately 3% of all ovarian cancers in
Western countries [1]. The following histological sub-
types exist: dysgerminoma, yolk sac tumour, embryonal
carcinoma, polyembryoma, choriocarcinoma, immature
teratoma, and mixed GCTs. Bilateral tumours occur in up
to 10% of cases [1,2]. The correct differential diagnosis is
imperative since the prognosis and choice of therapy
remain different among the various ovarian cancer types.
A treatment consisting of a combination of surgical resec-
tion and platinum-based chemotherapy cures the major-
ity of malignant OGCT patients [2]. The fact that OGCTs
often affect women in their reproductive years further
imply the importance of optimal therapy in order to max-
imize the number of women in which ovarian function
can be conserved.
Many similarities exist between GCTs of the ovary and tes-
tis, including a morphological resemblance and a similar
pattern of chromosomal alterations [3,4]. Furthermore,
families with both ovarian and testicular GCTs have been
reported, suggesting a possible association/common
genetic aetiology [5,6]. Ovaries and testes develop simi-
larly until approximately 2 months of embryonic life,
which is also consistent with a common origin of, at least
some cases of, ovarian and testicular GCTs. In this study,
recent knowledge of underlying mechanisms in develop-
ment of testicular GCTs was used as a guide to investigate
patterns of in situ protein expression in OGCTs. As a close
resemblance between testicular GCTs and embryonic
stem cells has been shown [7] particular focus was on
stem cell-related factors including KIT (also known as c-
Kit, tyrosine kinase receptor for stem cell factor (SCF)),
OCT-3/4 (POU5F1, a POU-family transcription factor),
NANOG, and AP-2γ (TFAP2C, transcription factor activa-
tor protein-2), and focus was also on germ cell-specific
proteins (including MAGE-A4 and NY-ESO-1 belonging
to the cancer/testis gene family) with a cell differentiation
related biological function or a developmentally regulated
expression pattern [8]. KIT is involved in the migration of
primordial germ cells (PGCs) [9] and there has been
reported a frequent presence of KIT mutations in GCTs
and in particular bilateral testicular GCTs [10-17]. There-
fore KIT mutation status was also determined in the same
samples and we established the expression pattern of pro-
teins not previously studied in the ovary during foetal
ovarian development. Finally, patients with intersex dis-
orders and dysgenetic ovaries have an increased risk of
harbouring a GCT, and the ovarian malignancies were
therefore investigated for the presence of Y-chromosome
material. Gonadoblastomas are rare neoplasms com-
posed of germ cells and immature granulosa/Sertoli cells
that develop nearly exclusively in males and phenotypic
females harbouring Y-chromosome material. We chose
TSPY as a marker, because this gene has been mapped to
a smallest region of the Y chromosome consistently
present in females with gonadoblastoma, and TSPY has
been proposed to be responsible for the origin of this
tumour [18]. We attempted to analyse the various steps
from the hypothesised development of some dysgermino-
mas from gonadoblastoma, considering why these neo-
plasias develop and progress.
Results
Immunohistochemistry pattern of expression in OGCTs 
and foetal ovaries
The expression pattern in OGCTs of a panel of markers for
testicular GCTs is summarised in Table 1 and illustrated in
Fig. 1 and 2. Placental alkaline phosphatase (PLAP), a
classical marker of GCTs, was expressed in 100% of dys-
germinomas, gonadoblastomas, embryonal carcinomas,
and in 46% of yolk sac tumours. Expression of the stem
cell-related markers OCT-3/4 and KIT were present in
80% of dysgerminomas, 75–100% of tumours containing
gonadoblastoma and in two yolk sac tumours, whereas
NANOG and AP-2γ were present in approximately half of
the dysgerminomas and gonadoblastomas. All bilateral (n
= 6) OGCTs were KIT positive. Overall the tumours con-
taining dysgerminoma and/or gonadoblastoma showed
expression of 0–4 stem cell markers (mean 2.5). Only one
dysgerminoma and one dysgerminoma with gonadoblas-
toma did not express any of the stem cell markers. Bilat-
eral cases expressed a mean of 3.4 stem cell markers,
whereas unilateral cases expressed a mean of 2.1 markers.
MAGE-A4 staining was present heterogeneously in 40% of
dysgerminomas and in 13% of dysgerminomas with
gonadoblastoma. No OGCTs showed expression of NY-
ESO-1 (CTAG1B/LAGE) or AMH (anti-Müllerian hor-
mone). As the OGCTs may develop in dysgenetic ovaries
with some testicular differentiation, we examined the
expression of AMH (anti-Müllerian hormone), a glyco-
protein involved in involution of Müllerian ducts in the
foetus leading to male differentiation [19], but did not
detect expression in any OGCTs. Analysed cores of
tumour tissues from mixed OGCTs did not differ in
expression pattern from cores from pure OGCTs. Most of
the markers expressed by dysgerminoma and gonadoblas-
toma were negative in non-dysgerminomas and none of
the ovarian small cell carcinomas expressed any of the
analysed markers. In foetal ovaries of all analysed ages,
strong expression of MAGE-A4 was detected in the major-
ity of oogonia (Fig. 2) and NY-ESO-1 in a subset of oogo-
nia. However, neither of the two was expressed in
developing follicles. NANOG and TSPY were not
expressed in foetal ovary of GW 13–40.Page 2 of 12
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Table 1: Protein expression of stem cell markers and others in OGCTs
HISTOLOGY of core N N bilat OCT-3/4 NANOG KIT AP-2γ TSPY MAGE-A4 NY-ESO-1 AMH PLAP HCG AFP
OVARIAN TISSUES
Foetal GW 13–18 4 OCT-3/4 in foetal 
ovary: Ref [21]
Neg KIT in foetal ovary: 
Ref [31]
AP-2γ in foetal 
ovary: Ref [27]
Neg Oogonia++ Oogonia+/- AMH in foetal 
ovary: Ref [19]
n.a. n.a. n.a.
Foetal GW 20–24 4 Neg Neg Oogonia++ Oogonia+/- n.a. n.a. n.a.
Foetal GW 34–40 4 Neg Neg Oogonia++ Oogonia+/- n.a. n.a. n.a.
DG 17 4 ++/+- 80% ++ 67% ++/+ 80%** ++/+ 33% +- 13% ++/+- 40% - ++/+- 100% ++ 7% ++ 7%
DG (w/GB)¤ 8 4 ++/+- 75% ++/+ 38% ++ 88%** +/+- 38% ++/+ 63% + 13% - - ++/+- 100% - -
GB 2 1 ++/+ 100% + 50% ++/+ 100%** - ++ 50% - - - ++ 100% - -
EC 1 - + 100% - - - - - - ++ 100% - -
YST 14 1 + 8% + 15% +/+- 15% - - - - - ++/+- 46% - ++/+- 77%
IT 17 - - - - - - - - - - +- 6%
CC 1 - - - - - - - - - ++ 100% -
SCC 8 - - - - - - - - - - -
NON-OVARIAN TISSUES
Adult normal testis 3 - +- (unsp) + 100%† - ++ 100%|| + 100%|| + 33%†† ++ 100%‡ - - -
CIS testis 2 ++ 100% ++ 100% ++ 100% ++ 100% ++ 100% - - - n.a. n.a. n.a.
Seminoma testis 2 ++ 100% ++ 100% ++ 100% ++ 50% ++ 100% - - - ++ 100% - -
EC/TER testis 2 ++ 100% ++ 100% + 50% ++/+ 100% + 100% - - - ++/+ 100% ++ 100% + 50%
YST testis 1 ++ 100% ++ 100% - - - - - - + 100% ++ 100% ++ 100%
Colon cancer 2 - - - - - - - - - - -
Prostate cancer 2 - - - - - - - - - - -
Normal brain 1 - - - - - - - - - - -
Normal kidney 1 - - - (unsp) - (unsp) +- (unsp) - - - - - -
Normal liver 2 - - - (unsp) - (unsp) - - - - - - -
Staining intensity is marked by '++'/'+'/'+-'/'-' followed by the percentage of positive tissue samples. Staining intensity = '++': >50%, of tumour cells stained; '+': staining in approximately 20–50% of tumour cells; '+-': few cells stained; '-': no positive 
cells detected. For each tumour type the range of staining intensities are divided with '/'. Symbols = †: staining in spermatocytes; ||: staining in spermatocytes and spermatogonia; ††: staining in spermatogonia; ‡: staining in pre-pubertal Sertoli cells; 
**: all bilateral DG or GB stained '++' with KIT; ¤: DG tissue from patients with diagnosis DG with GB. Abbreviations: OGCT = ovarian germ cell tumour; GW = gestational week; DG = dysgerminoma; GB = gonadoblastoma; EC = embryonal 
carcinoma; YST = yolk sac tumour; IT = immature teratoma; CC = choriocarcinoma; SCC = small cell carcinoma; CIS = carcinoma in situ; TER = teratoma; N = number; bilat = bilateral; n.a. = not analysed; ref = reference; unsp = unspecific.
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Expression of stem cell related markers and KIT mutations in dygerminomasFigure 1
Expression of stem cell related markers and KIT mutations in dygerminomas. A. Immunohistochemical staining for 
OCT-3/4, KIT, NANOG, and AP-2γ in dysgerminomas. Scale bar = 25 μm. B. Examples of KIT mutation analysis, with control 
sequence from normal blood, and three of the mutated KIT (codon 816) sequences from dysgerminomas.
Molecular Cancer 2007, 6:12 http://www.molecular-cancer.com/content/6/1/12Analysis of tumour DNA for KIT gene mutations
PCR amplification was performed on 52 tumour DNA
samples from 43 patients (Table 2 and Fig. 3). KIT was
mutated in codon 816 in 5/14 unilateral dysgerminomas,
whereas all dysgerminomas from bilateral cases (n = 4)
showed a wild type sequence, as did all OGCTs of other
histotypes (n = 22). A mutation of G to C in the first base
of the codon (GAC to CAC) was found once, whereas a G
to T (GAC to TAC) was detected in two cases. The second
base exchange GAC to GTC was also detected in two cases.
The mutations in KIT were not linked to KIT protein over-
expression, as 2/5 samples containing mutations were
negative for KIT. On the other hand, all cores from bilat-
eral cases were KIT positive by immunohistochemistry.
Presence of Y-chromosome material in dysgerminoma/
gonadoblastoma samples
TSPY protein was present in six tumour tissue cores from
five patients, all harbouring dysgerminoma and/or gona-
doblastoma elements. Four of five patients had bilateral
neoplasia. Immunohistochemistry for TSPY was then
repeated on whole tumour sections with identical results.
Karyotypes of normal tissues (e.g. blood cells) of the
OGCT patients were not available in the majority of cases,
In situ expression pattern of germ cell-related markers (MAGE-A4 and TSPY) in OGCTs and sex centromere material in inter-phase nuclei fr m OGCTsFigur  2
In situ expression pattern of germ cell-related markers (MAGE-A4 and TSPY) in OGCTs and sex centromere 
material in interphase nuclei from OGCTs. MAGE-A4 in A1: Dysgerminoma and A2: In foetal ovary of GW 28 with 
strong expression in oogonia (lower left), and no expression in developing follicles (top right); TSPY in B1: Gonadoblastoma 
(Case PT-04) and B2: Dysgerminoma (Case PT-57). Scalebar = 25μm. Fluorescence in situ hybridisation of two different dys-
germinomas with sex chromosome centromeres: C. Presence of X and Y chromosome material (Case PT-04) and D. Presence 
only of X chromosome material (Case PT-14). E-F: Inserts are control DAPI-only.Page 5 of 12
(page number not for citation purposes)
Molecular Cancer 2007, 6:12 http://www.molecular-cancer.com/content/6/1/12therefore we performed FISH with a centromeric probe for
the Y chromosome on 27 sections containing dysgermi-
noma and/or gonadoblastoma, of which 19 were conclu-
sive. Y-chromosome material was detected sections from
five patients, and these were the patients harbouring
TSPY-positive cells. In three other tissues staining was
judged as unspecific, with no Y-chromosome material
detected by FISH. Analysis on 12 non-dysgerminoma/
gonadoblastoma samples (1 embryonal carcinoma, 7
yolk sac tumours, 4 immature teratomas) showed only X
chromosome signal. Y-chromosome material was present
in all control testicular GCTs (seminoma, yolk sac
tumour, embryonal carcinoma). Examples are shown in
Fig. 2.
Discussion
In this study, we provide novel evidence for distinct, partly
overlapping mechanisms acting in the pathogenesis of
OGCTs. To our knowledge, this study is the first compre-
hensive analysis of an in situ protein expression profile of
pluripotency genes and germ cell differentiation markers
in these relatively rare malignant tumours. The expression
of the transcription factors OCT-3/4 and NANOG were of
particular interest, as they are key regulators of self-
renewal and pluripotency of embryonic stem cells. In
addition to the role in early embryonic development,
these proteins are only present in PGCs, oogonia and
gonocytes and in the testis only in malignant GCTs [20-
22]. In the present study, OCT-3/4 expression was abun-
dant in all gonadoblastomas and most dysgerminomas,
in accordance with previously published data [23].
NANOG has not previously been evaluated in the ovary.
Approximately half of the dysgerminomas and gonadob-
lastomas expressed NANOG, whereas tumours with
somatic differentiation were largely negative. We did not
detect NANOG expression in foetal ovaries, but cannot
Table 2: DNA sequence status of KIT exon 17 and expression of KIT in OGCTs
Patient ID Histology of core Bilateral KIT protein expression KIT mutation in codon 816, exon 17
PT-09 DG (w/GB) - GAC to TAC, Asp to Tyr
PT-16 DG + GAC to TAC, Asp to Tyr
PT-49 DG ++ GAC to CAC, Asp to His
PT-52 DG ++ GAC to GTC, Asp to Val
PT-58 DG - GAC to GTC, Asp to Val
PT-04 DG Bilateral ++ wt
GB Bilateral ++ wt
PT-32 DG Bilateral ++ wt
YST Bilateral - wt
PT-35 DG (left ovary) Bilateral ++ wt
DG (right ovary) Bilateral ++ wt
PT-57 GB Bilateral M wt
DG (left ovary) Bilateral ++ wt
DG (right ovary) Bilateral ++ wt
PT-03 DG (w/GB) ++ wt
EC - wt
GB - wt
PT-15 DG M wt
PT-19 DG - wt
PT-27, 39 DG ++ wt
PT-40 DG (w/GB) ++ wt
PT-48 DG + wt
PT-53 CC - wt
DG + wt
PT-28 DG ++ wt
YST - wt
PT-08 YST M wt
PT-20 YST + wt
PT-25,33,43,45,54,55 YST - wt
PT-06,10,18,23,31,34,44,46,47,51 IT - wt
PT-12, 22 IT M wt
PT-36, 37 YST, IT - wt
PT-11, 59, 56 SCC - wt
Staining intensity = '++': >50%, of tumour cells stained; '+': staining in approximately 20–50% of tumour cells; '+-': few cells stained; '-': no positive 
cells detected. Abbreviations: DG = dysgerminoma; GB = gonadoblastoma; YST = yolk sac tumour; EC = embryonal carcinoma; CC = 
choriocarcinoma; IT = immature teratoma; OGCT = ovarian germ cell tumour; PT = patient; SCC = small cell carcinoma; M = missing; wt = wild 
type.Page 6 of 12
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Molecular Cancer 2007, 6:12 http://www.molecular-cancer.com/content/6/1/12exclude expression in first trimester. Murine foetal ovary
expresses Nanog in early foetal development with earlier
downregulation than in male gonads [24]. Our results
indicate that in analogy to the mouse model, NANOG
could to be earlier down-regulated in human foetal ovary
than testis, where gonocytes abundantly express NANOG
until GW 20 [22].
The tissue specific adult stem cell-related factors AP-2γ
and KIT are highly expressed in immature gonocytes, tes-
ticular carcinoma in situ (the pre-invasive stage of testicu-
lar GCTs) and in seminomas, and AP-2γ, but not KIT, is
expressed in embryonal carcinoma [25-27]. AP-2γ expres-
sion was previously reported in ovarian carcinomas [28]
and in 5/5 dysgerminomas [29]. In contrast to the male
pattern, AP-2γ was only expressed in 33% of dysgermino-
mas and 38% of dysgerminomas containing gonadoblas-
toma. Higher oestrogen levels in the ovaries may in part
explain the observed difference, as AP-2γ has been sug-
gested involved in oestrogen signalling [27]. The role of
AP-2γ in the gonads has not yet been elucidated but dis-
ruption of the gene in mice leads to complete loss of germ
cells, probably because of failure of KIT induction, which
is hypothesised to be a main target for AP-2γ[30].
The KIT/SCF system is of particular interest in regard to
the origin of GCTs, due to a role in PGC proliferation and
survival in the developing human gonad [9]. KIT expres-
sion was previously described in oogonia and oocytes
[25,31,32] and in some OGCTs, predominantly dysgermi-
nomas [33-35]. In accordance with these reports, we
found KIT expressed in 80–100% of neoplastic cells in
dysgerminomas and gonadoblastomas, and in 15% of
yolk sac tumours. The high expression of KIT in dysgermi-
noma prompted us to investigate the possibility of a gene
mutation. A gain-of-function mutation in the KIT gene
was first reported in human GCTs, including one ovarian
dysgerminoma/yolk sac tumour by Tian et al. [10] and
A model for development of ovarian and testicular germ cell tumoursFigure 3
A model for development of ovarian and testicular germ cell tumours. * usually including Y chromosome material.Page 7 of 12
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Molecular Cancer 2007, 6:12 http://www.molecular-cancer.com/content/6/1/12later studies have shown KIT mutations in a varying pro-
portion of phenotypically indistinguishable testicular
seminomas [12,14,15,36], primary mediastinal semino-
mas [11] and intracranial germinomas, both in males and
females [13,17]. Among 11 OGCTs previously analysed
for KIT mutations two (one unilateral case – for the other
such info was not given) had a GAC to CAC change in
codon 816 [10,14,16]. We detected five KIT mutations in
the same codon, but found three different base changes in
five OGCTs (four pure dysgerminomas and one dysgermi-
noma with gonadoblastoma). Strikingly, all mutations
were found in unilateral cases and none among four ana-
lysed bilateral cases. This could suggest that KIT mutations
occur after completion of PGC migration to the gonadal
ridges in females, and may be in contrast to what has been
suggested for males, where some reports have shown KIT
mutations more frequently in bilateral seminomas
[12,15]. We hypothesise that activating KIT mutation(s)
in early oogonia may stimulate their proliferation and
delay meiotic entry, which in normal ovaries occurs grad-
ually in foetal life, thus increasing the pool of immature
germ cells.
It has been proposed that dysgerminoma may evolve from
gonadoblastoma [37,38]. We analysed the stages of
tumour development, from pure gonadoblastoma,
through dysgerminoma with gonadoblastoma, to pure
dysgerminoma, using the TSPY gene, a proposed GBY
gene, as a marker. Besides gonadoblastoma, TSPY is
expressed in male pre-meiotic germ cells and testicular
GCTs that retain germ cell phenotype [18,39,40]. We
found abundant TSPY in 5/7 cases of gonadoblastoma or
dysgerminoma with gonadoblastoma, but not in pure
dysgerminoma (n = 11). Consistent results were detected
with TSPY protein and FISH Y-centromere analyses, sug-
gesting that TSPY is included in the sub-region of the Y-
chromosome involved. In one case of combined dysger-
minoma/gonadoblastoma we detected a KIT mutation.
Taken together, these results indicate that development of
dysgerminoma with gonadoblastoma versus pure dysger-
minoma may follow different molecular routes, with a
role for one or more Y-chromosome genes in the develop-
ment of gonadoblastoma in phenotypic females. Sex-
chromosome alteration leads to gonadal dysgenesis and
partial masculinisation in at least some cells of the devel-
oping female ovary. This may lead to a delay of the nor-
mal differentiation of germ cells in foetal ovaries and a
failure of the onset of meiotic prophase, thus increasing
the chance of mutational events (e.g. in KIT) and neoplas-
tic transformation in the mitotically dividing germ cells,
perhaps stimulated by pleiotrophic action of TSPY.
As the OGCTs may develop in dysgenetic ovaries with
some testicular differentiation, we examined the expres-
sion of AMH, a glycoprotein involved in involution of
Müllerian ducts in the foetus leading to male differentia-
tion [19], but did not detect expression in any OGCTs. We
furthermore examined MAGE-A4 and NY-ESO-1 [41], two
representatives of the germ cell-specific "cancer/testis"
gene family on the X-chromosome, which appear in
gonocytes from around gestational week 17–18 at differ-
entiation into pre-spermatogonia, and are expressed in
adult spermatogonia and primary spermatocytes, as well
as in some testicular tumours and a broad range of
somatic cancers [42,43]. In accordance with previous
studies [43,44] we detected expression of MAGE-A4 and
NY-ESO-1 in foetal oogonia/oocytes of 13–40 weeks of
gestational age. MAGE-A4 and NY-ESO-1 have been
reported in ovarian epithelial and serous carcinomas [45],
but this is the first study regarding OGCTs. We found a
heterogeneous expression of MAGE-A4 but not NY-ESO-1
in dysgerminomas, analogous to the pattern in testicular
seminomas.
In this study, we included also some small cell carcinomas
of the hypercalcaemic type that occasionally develop in
the ovaries of young patients. None of the applied mark-
ers were positive, and therefore it is unlikely that small cell
carcinomas have a germ cell progenitor, as has been sug-
gested [46,47]. With regard to the immature teratomas,
they were also negative for all analysed markers, which
may support the observation that this tumour, which is
usually diploid and does not have the isochromosome
(12p) imbalance, probably develops in a different man-
ner than other malignant OGCTs [3,4]. No KIT mutations
or presence of Y-chromosome material was detected in
any of the small cell carcinomas or immature teratomas.
We detected many similarities, but also some notable dif-
ferences in the protein expression profiles of ovarian and
testicular GCTs, but nevertheless propose a comparable
developmental model, as depicted in Fig. 3. Genetic alter-
ations and biological mechanisms may be identical, with
abnormal persistence of undifferentiated PGCs in both
sexes, with the large difference in incidence reflecting the
much lower number of susceptible cells in females at the
time of puberty [48]. The proposed stepwise progression
from gonadoblastoma to dysgerminoma in dysgenetic
ovaries [38], and the similarities of gonadoblastoma and
testicular carcinoma in situ [49], could indicate that gona-
doblastoma – analogous to carcinoma in situ in the testes
– is a precursor stage, which probably only occurs in phe-
notypic females with Y-chromosome material. As the stem
cell-related markers were abundantly expressed, our
hypothesis is that in 46, XX females, the OGCTs probably
are derived from PGCs or oogonia. We speculate that
despite the lack of the Y-chromosome material, some
degree of gonadal dysgenesis leading to a delay in the dif-
ferentiation of PGC/oogonia and initiation of gonadob-
lastoma-like lesions, may be due to changes in hormonalPage 8 of 12
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by lifestyle changes, e.g. obesity. However, the low inci-
dence of OGCTs complicates establishment of epidemio-
logical associations.
Conclusion
We provide in this study new evidence for two partially
overlapping mechanisms that may contribute to the
pathogenesis of ovarian germ cell neoplasms. One mech-
anism is related to the presence of Y-chromosome mate-
rial and ensuing gonadal dysgenesis. The other
mechanism is primarily genetic and involves spontaneous
mutation(s) in the KIT gene, leading to increased survival
and proliferation of undifferentiated oogonia. We expect
this mechanism not to be limited to KIT, but demonstrate
that mutations in KIT are responsible for a sizeable
number (5/17) of cases containing dysgerminoma. The
neoplastic transformation must occur before oocytes
enter meiosis, most likely after the migration to the
gonadal ridges, as the mutations were detected in unilat-
eral tumours.
Methods
Tissue samples
The samples originated from patients diagnosed between
1983–2001, who were admitted to 18 Norwegian hospi-
tals for surgery and subsequently referred to the Norwe-
gian Radium Hospital for adjuvant treatment. The tissue
microarray (TMA) consisted of 60 cores from tumours of
50 OGCTs patients as described in Table 3. The TMA also
contained tissue cores of ovarian small cell carcinoma (n
= 8) and various non-ovarian normal and neoplastic tis-
sues, see Table 1. For studies of the ontogeny of expression
of selected proteins, we used normal foetal ovarian speci-
mens, which were obtained after induced or spontaneous
abortions and stillbirths, mainly due to placental or
maternal problems (n = 12, from Rigshospitalet, Copen-
hagen University Hospital). Developmental age was cal-
culated according to menstrual bleeding and foetal foot
size [25]. A representative series of paraffin-embedded tes-
ticular GCT samples from the tissue bank at Rigshospitalet
was used for positive controls. The Norwegian ethical
guidelines were followed and the biobank is registered at
the Norwegian Institute of Public Health. The Regional
Committee for Medical Research Ethics in Denmark
approved the use of Danish tissue samples.
Immunohistochemistry
The protein expressions were analysed by immunohisto-
chemistry on 4 μm formalin-fixed, paraffin-embedded
sections. The following antibodies were used: OCT-3/4
(C-10, sc-5279) and AP-2γ (6E4/4, sc-12762) from Santa
Cruz Biotechnology, CA); NANOG (14-5769) from eBio-
science, San Diego, CA; TSPY from Y.-F.C. Lau, VA Medical
Center, University of CA, San Francisco; MAGE-A4 and
NY-ESO-1 from G. Spagnoli, Ludvig Institute for Cancer
Research, Switzerland; AMH from R.L. Cate, Biogen, MA;
HCG (A0023), KIT (CD117, A4502), and AFP (A0008)
from DakoCytomation, Glostrup, Denmark; PLAP (NCL-
PLAP-8A9) from NovoCastra, Newcastle, UK. A previ-
ously published standard indirect peroxidase method was
applied with small adjustments [19]. Briefly, most of the
dewaxed and rehydrated sections were heated in a micro-
wave oven in one of the following buffers: TEG-buffer =
TRIS 1.21 g/L, EGTA 0.19 g/L, pH 9.0 (OCT-3/4, KIT,
TSPY); Tris EDTA-buffer = 1.2 g/L TRIS, 0.37 g/L EDTA
(HCG); 5% Urea-buffer, pH 8.5 (AP-2γ, AMH); Citrate-
buffer = 10 mmol/L, pH 6.0 (NANOG, MAGE-A4); Target
Retrieval Solution (DakoCytomation), low pH (PLAP)
and high pH (AFP)). Sections were then incubated with
1.5% H2O2, followed by diluted non-immune goat serum
or human serum. Incubation with the diluted primary
antibody was overnight at 4°C (dilution OCT-3/4 1:300;
NANOG 1:80; KIT 1:400; AP-2γ 1:50; TSPY 1:7000;
MAGE-A4 1:200; NY-ESO-1 1:50; AMH 1:150; HCG
1:4000; PLAP 1:20; AFP 1:800). A serial section was incu-
bated with dilution buffer for each investigation as nega-
tive control. Subsequently, a secondary biotinylated link
antibody was applied, followed by the horseradish perox-
idase-streptavidin complex (all reagents from Zymed, S.
San Francisco, CA). Visualization was with Envision+
(DakoCytomation, AFP, HCG, PLAP) or aminoethyl car-
bazole substrate (Zymed, all other antibodies) and coun-
terstaining with Mayer's haematoxylin.
To define the pattern of expression of the analysed pro-
teins and to control for specificity of all antibodies, we
analysed expression patterns in various normal tissues,
testicular GCTs, and non-gonadal malignancies and
results were in accordance with previously reported
expression patterns (Table 1).
Evaluation was performed independently by V.M.A and
C.E.H.H. by a semi-quantitative score (Table 1) after
transfer of the TMA images to a computer by a high-reso-
lution camera (Sony DFW-SX900 CCD Digital Color
Camera) using an in-house developed software (Dept.
Medical Informatics, Rikshospitalet-Radiumhospitalet
Medical Centre, Oslo, Norway) enabling examination of
several cores simultaneously. When discrepancy arose
cores were re-evaluated and a consensus reached.
KIT mutation analysis, codon 816
Mutation analysis of the KIT gene was focused on exon 17,
in which the most commonly mutated codon 816 is
located. Analysis was performed by PCR and direct
sequencing. Genomic DNA was extracted from formalin-
fixed, paraffin-embedded tissue, as described in [4] and
amplified with the primers: KIT exon 17-F: 5'-TTTCTC-
CTCCAACCTAATAG-3', KIT exon 17-R: 5'-CCTTTGCAG-Page 9 of 12
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HotStarTaq DNA Polymerase (Qiagen, Hilden, Germany)
and 10× HotStar buffer with 15 mM MgCl2, with amount
of template between 25–200 ng in a total reaction volume
of 25 μl. Amplification was performed by: 95°C for 15
min of initial heat denaturation followed by 35–40 cycles
of 94°C for 30 sec, 48–52°C for 30 sec, and 72°C for 30
sec, followed by 72°C for 8 min. The PCR products were
purified with ExoSAP-IT containing Exonuclease 1 and
Shrimp Alkaline Phosphatase (USB, Cleveland, Ohio)
and subsequently directly sequenced with the BigDye Ter-
minator v1.1 Cycle Sequencing Kit (Applied Biosystems,
Foster City, CA). Briefly; 1 μl ready reaction mix, 1 μl PCR-
product, 1,5 pmol of sequence primer, 1,5 μl BigDye
buffer, and MilliQ-water up to a total reaction volume of
10 μl. Forward and reverse sequencing was performed
with an Applied Biosystems 3730 DNA Analyzer with
independent analysis by two researchers.
Fluorescence in situ hybridisation (FISH)
FISH was performed to analyse the presence of X and Y-
chromosome material. Preparation of the sections was
similar to that described above for immunohistochemis-
try. Sections were deparaffinised, rehydrated and pre-
treated with proteinase K solution/PBS (20 μg/ml, Invitro-
gen, Carlsbad, CA). Dehydration was applied before
denaturation of slides together with the probes specific for
centromeres of the X-chromosome (Texas red labelled)
and the Y-chromosome (FITC labelled, green fluores-
cence) (probes from DakoCytomation). Sections were
hybridised for 2 h, washed, dehydrated and mounted in
Antifade with DAPI II (125 ng/ml, Vysis Inc., IL), followed
by examination using an epifluorescence microscope
(Leica, Wetzlar, Germany) with 100× magnification and
the CytoVysion software (Applied Imaging, Newcastle,
UK).
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